Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

PHASE3CompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

February 14, 2020

Conditions
PruritusPrurigo Nodularis
Interventions
DRUG

5mg Serlopitant Tablets

Serlopitant Tablets

DRUG

Placebo Tablets

Placebo Tablets

Trial Locations (49)

10025

Study Site 500, New York

10075

Study Site 517, New York

11203

Study Site 507, Brooklyn

14221

Study Site 508, Buffalo

15213

Study Site 522, Pittsburgh

19104

Study Site 523, Philadelphia

20769

Study Site 525, Glenn Dale

26505

Study Site 532, Morgantown

27262

Study Site 341, High Point

30263

Study Site 510, Newnan

33134

Study Site 210, Coral Gables

33155

Study Site 531, Miami

33162

Study Site 222, North Miami Beach

33165

Study Site 530, Miami

33180

Study Site 501, Aventura

33316

Study Site 534, Fort Lauderdale

35233

Study Site 504, Birmingham

37215

Study Site 805, Nashville

37317

Study Site 511, Knoxville

40202

Study Site 228, Louisville

43016

Study Site 524, Dublin

43209

Study Site 516, Bexley

44106

Study Site 509, Cleveland

48103

Study Site 506, Ann Arbor

48202

Study Site 515, Detroit

60077

Study Site 388, Skokie

63110

Study Site 528, St Louis

64506

Study Site 371, Saint Joseph

68144

Study Site 227, Omaha

70115

Study Site 527, New Orleans

72758

Study Site 533, Rogers

74136

Study Site 112, Tulsa

75231

Study Site 502, Dallas

77004

Study Site 224, Houston

77401

Study Site 520, Bellaire

77598

Study Site 226, Webster

78213

Study Site 361, San Antonio

78660

Study Site 359, Pflugerville

78745

Study Site 365, Austin

89052

Study Site 526, Henderson

91606

Study Site 383, North Hollywood

92108

Study Site 356, San Diego

92701

Study Site 514, Santa Ana

94538

Study Site 204, Fremont

99202

Study Site 806, Spokane

02114

Study Site 379, Boston

08520

Study Site 201, East Windsor

07044-2946

Study Site 529, Verona

02919

Study Site 345, Johnston

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT03546816 - Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis | Biotech Hunter | Biotech Hunter